Lord, Abbett & Co’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-891,390
| Closed | -$29.6M | – | 571 |
|
|
2023
Q3 | $29.6M | Sell |
891,390
-1,574,816
| -64% | -$55.7M | 0.11% | 254 |
|
|
2023
Q2 | $90.5M | Sell |
2,466,206
-432,990
| -15% | -$16.9M | 0.31% | 92 |
|
|
2023
Q1 | $118M | Sell |
2,899,196
-1,507,566
| -34% | -$65.1M | 0.43% | 58 |
|
|
2022
Q4 | $226M | Sell |
4,406,762
-1,369,807
| -24% | -$65.7M | 0.81% | 16 |
|
|
2022
Q3 | $253M | Sell |
5,776,569
-205,621
| -3% | -$9.99M | 0.92% | 15 |
|
|
2022
Q2 | $314M | Sell |
5,982,190
-1,389,706
| -19% | -$70.8M | 1.11% | 8 |
|
|
2022
Q1 | $382M | Buy |
7,371,896
+495,987
| +7% | +$25.7M | 1.02% | 9 |
|
|
2021
Q4 | $406M | Buy |
6,875,909
+5,125,851
| +293% | +$254M | 0.93% | 7 |
|
|
2021
Q3 | $75.3M | Buy |
+1,750,058
| New | +$77.5M | 0.18% | 174 |
|
|
2020
Q3 | – | Sell |
-938,271
| Closed | -$29.1M | – | 669 |
|
|
2020
Q2 | $29.1M | Sell |
938,271
-2,616,304
| -74% | -$88.9M | 0.1% | 306 |
|
|
2020
Q1 | $110M | Sell |
3,554,575
-165,252
| -4% | -$5.63M | 0.49% | 46 |
|
|
2019
Q4 | $138M | Sell |
3,719,827
-230,090
| -6% | -$8.2M | 0.46% | 47 |
|
|
2019
Q3 | $135M | Sell |
3,949,917
-590,907
| -13% | -$21.5M | 0.46% | 38 |
|
|
2019
Q2 | $187M | Sell |
4,540,824
-1,580,309
| -26% | -$62.8M | 0.61% | 17 |
|
|
2019
Q1 | $247M | Buy |
6,121,133
+277,886
| +5% | +$11.1M | 0.82% | 8 |
|
|
2018
Q4 | $242M | Sell |
5,843,247
-707,655
| -11% | -$29.4M | 0.88% | 9 |
|
|
2018
Q3 | $274M | Buy |
6,550,902
+601,494
| +10% | +$23.2M | 0.76% | 8 |
|
|
2018
Q2 | $205M | Sell |
5,949,408
-147,982
| -2% | -$5.06M | 0.6% | 17 |
|
|
2018
Q1 | $205M | Sell |
6,097,390
-284,602
| -4% | -$9.78M | 0.61% | 15 |
|
|
2017
Q4 | $219M | Sell |
6,381,992
-956,224
| -13% | -$32.6M | 0.62% | 13 |
|
|
2017
Q3 | $249M | Sell |
7,338,216
-1,195,794
| -14% | -$38.4M | 0.73% | 7 |
|
|
2017
Q2 | $272M | Sell |
8,534,010
-2,543,865
| -23% | -$80.2M | 0.81% | 6 |
|
|
2017
Q1 | $360M | Sell |
11,077,875
-2,043,290
| -16% | -$64.4M | 1.08% | 4 |
|
|
2016
Q4 | $404M | Buy |
13,121,165
+429,218
| +3% | +$13.1M | 1.23% | 3 |
|
|
2016
Q3 | $408M | Sell |
12,691,947
-808,799
| -6% | -$27M | 1.24% | 2 |
|
|
2016
Q2 | $451M | Buy |
13,500,746
+408,210
| +3% | +$13M | 1.41% | 1 |
|
|
2016
Q1 | $368M | Sell |
13,092,536
-3,129,070
| -19% | -$89.4M | 1.16% | 3 |
|
|
2015
Q4 | $497M | Sell |
16,221,606
-440,831
| -3% | -$13.9M | 1.49% | 3 |
|
|
2015
Q3 | $497M | Sell |
16,662,437
-1,361,917
| -8% | -$43.7M | 1.5% | 1 |
|
|
2015
Q2 | $573M | Sell |
18,024,354
-2,292,503
| -11% | -$74.7M | 1.51% | 2 |
|
|
2015
Q1 | $671M | Buy |
20,316,857
+10,637,782
| +110% | +$338M | 1.7% | 2 |
|
|
2014
Q4 | $286M | Sell |
9,679,075
-466,127
| -5% | -$13.4M | 0.73% | 10 |
|
|
2014
Q3 | $285M | Sell |
10,145,202
-122,462
| -1% | -$3.44M | 0.71% | 15 |
|
|
2014
Q2 | $289M | Sell |
10,267,664
-376,882
| -4% | -$10.7M | 0.66% | 11 |
|
|
2014
Q1 | $324M | Sell |
10,644,546
-254,223
| -2% | -$7.58M | 0.74% | 5 |
|
|
2013
Q4 | $317M | Buy |
10,898,769
+252,339
| +2% | +$7.34M | 0.7% | 12 |
|
|
2013
Q3 | $289M | Buy |
10,646,430
+900,220
| +9% | +$24.5M | 0.67% | 14 |
|
|
2013
Q2 | $259M | Buy |
+9,746,210
| New | +$269M | 0.6% | 22 |
|
Other funds holding PFE
Lord, Abbett & Co's PFE Position: Q4 2023 in Review
Lord, Abbett & Co sold out of Pfizer (PFE) in Q4 2023, closing a stake of 891,390 shares — an estimated $29.6M sold.
Lord, Abbett & Co first reported a position in PFE in Q2 2013 and held it in 38 quarters. The position peaked at $671M in Q1 2015. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.
- Lord, Abbett & Co reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
- Lord, Abbett & Co sold 891,390 Pfizer shares in Q4 2023, an estimated $29.6M.
- Lord, Abbett & Co first reported a position in Pfizer in Q2 2013 and held it in 38 quarters.
- Lord, Abbett & Co's Pfizer position peaked at $671M in Q1 2015.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.
Based on Lord, Abbett & Co's 13F filing for Q4 2023, filed 12 Feb 2024.